IL13RA2 Immunogenic Compounds for Tumor-Specific T-Cell Activation

The patent segments the immune system into specific T-cell populations that can be selectively activated against tumor antigens. By using antigenic peptides that bind to specific MHC molecules, the therapy targets only tumor cells expressing those antigens, leaving normal tissues unaffected. This segmentation approach replaces the non-specific damage of traditional therapies with precise immune cell-mediated tumor elimination.

The patent introduces antigenic peptides as intermediaries that bridge the immune system and tumor cells. These peptides are derived from tumor antigens and serve as mediators to activate T-cells specifically against tumor cells. The peptides act as a communication bridge, allowing the immune system to recognize and attack tumor cells without damaging normal tissues, thus resolving the contradiction between tumor control and tissue protection.

The patent applies parameter changes by modifying the antigenic peptide sequences to optimize their binding affinity to specific MHC molecules. By changing the amino acid parameters of the peptides, the therapy enhances immune recognition and activation. Additionally, the patent changes the parameter of antigen diversity by using multiple different antigenic peptides targeting different tumor antigens, thereby overcoming patient heterogeneity and resistance through multi-targeted immune activation.

The patent achieves universality by developing a platform that can target multiple different tumor antigens across various cancer types. The antigenic peptides are designed to bind to common MHC molecules (HLA-A*02:01, HLA-A*24:02) that are expressed on most human cells, making the therapy universally applicable. This multi-functional approach allows a single therapeutic strategy to work across different patients and cancer types, reducing intrinsic resistance.